Akari Therapeutics Plc
For the period ended Dec 31, 2024. Filed Apr 15, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 15, 2025
AKTX$7.13-6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets at December 31, 2024 and 2023
(amounts in thousands, except share and per share data)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash | $2,599 | $3,845 |
| Restricted cash | 60 | — |
| Prepaid expenses | 92 | 299 |
| Other current assets | 201 | 197 |
| Total current assets | 2,952 | 4,341 |
| Goodwill | 8,430 | — |
| Other intangible assets | 39,180 | — |
| Patent acquisition costs, net | — | 14 |
| Total assets | $50,562 | $4,355 |
| LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT) | ||
| Current liabilities: | ||
| Accounts payable | $12,407 | $1,671 |
| Accrued expenses | 3,137 | 1,566 |
| Convertible notes | 700 | — |
| Convertible notes, related party | 250 | — |
| Notes payable | 659 | — |
| Notes payable, related party | 1,651 | — |
| Warrant liabilities | 1,012 | 1,253 |
| Other current liabilities | 94 | 94 |
| Total current liabilities | 19,910 | 4,584 |
| Other non-current liabilities | 383 | — |
| Deferred tax liability | 8,040 | — |
| Total liabilities | 28,333 | 4,584 |
| Commitments and contingencies (Note 10) | ||
| Shareholders’ equity (deficit): | ||
| Share capital of $0.0001 par value | ||
| Authorized: 245,035,791,523 and 45,122,321,523 ordinary shares at December 31, 2024 and 2023, respectively; issued and outstanding: 53,186,919,523 and 13,234,315,298 at December 31, 2024 and 2023, respectively | 5,319 | 1,324 |
| Additional paid-in capital | 212,706 | 174,754 |
| Capital redemption reserve | 52,194 | 52,194 |
| Accumulated other comprehensive loss | (738) | (1,040) |
| Accumulated deficit | (247,252) | (227,461) |
| Total shareholders’ equity (deficit) | 22,229 | (229) |
| Total liabilities and shareholders’ equity (deficit) | $50,562 | $4,355 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.